Latest news with #StephenCarey
Globe and Mail
01-08-2025
- Business
- Globe and Mail
ANI Pharmaceuticals to Discuss Second Quarter 2025 Financial Results on August 8, 2025, at 8:30 a.m. ET
PRINCETON, N.J., Aug. 01, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. ('ANI' or the 'Company') (NASDAQ: ANIP) today announced that the Company will release its second quarter 2025 financial results on Friday, August 8, 2025, prior to the market open. Nikhil Lalwani, President and Chief Executive Officer, Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, Chris Mutz, Head of Rare Disease, and Mary Pao, M.D., Ph.D., Chief Medical Officer, will host a conference call to discuss the results as follows: Date Friday, August 8, 2025 Time 8:30 a.m. ET Toll free (U.S.) 800-343-4136 Conference ID 5034065 Webcast (live and replay) under the 'Investors' section A replay of the conference call will be available within two hours of the call's completion and will remain accessible for two weeks by dialing 800-839-6803 and entering access code 5034065. About ANI Pharmaceuticals, Inc. ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company committed to its mission of 'Serving Patients, Improving Lives" by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The Company is focused on delivering sustainable growth through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; its Generics business, which leverages R&D expertise, operational excellence, and U.S.-based manufacturing; and its Brands business. For more information, visit
Yahoo
01-08-2025
- Business
- Yahoo
ANI Pharmaceuticals to Discuss Second Quarter 2025 Financial Results on August 8, 2025, at 8:30 a.m. ET
PRINCETON, N.J., Aug. 01, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. ('ANI' or the 'Company') (NASDAQ: ANIP) today announced that the Company will release its second quarter 2025 financial results on Friday, August 8, 2025, prior to the market open. Nikhil Lalwani, President and Chief Executive Officer, Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, Chris Mutz, Head of Rare Disease, and Mary Pao, M.D., Ph.D., Chief Medical Officer, will host a conference call to discuss the results as follows: Date Friday, August 8, 2025 Time 8:30 a.m. ET Toll free (U.S.) 800-343-4136 Conference ID 5034065 Webcast (live and replay) under the 'Investors' section A replay of the conference call will be available within two hours of the call's completion and will remain accessible for two weeks by dialing 800-839-6803 and entering access code 5034065. About ANI Pharmaceuticals, Inc. ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company committed to its mission of 'Serving Patients, Improving Lives" by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The Company is focused on delivering sustainable growth through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; its Generics business, which leverages R&D expertise, operational excellence, and U.S.-based manufacturing; and its Brands business. For more information, visit Investor Relations Contact:Lisa M. Wilson, In-Site Communications, Inc.212-452-2793lwilson@ SOURCE: ANI Pharmaceuticals, Inc.
Yahoo
13-05-2025
- Business
- Yahoo
ANI Pharmaceuticals to Participate at the H.C. Wainwright 3rd Annual BioConnect Conference at NASDAQ
PRINCETON, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ as follows: Date: Tuesday, May 20, 2025 Time: 1:30pm ET Webcast: Click Here To schedule a 1x1 meeting with management, please contact meetings@ The live and archived webcast will be accessible from the Company's website at under the Investors section under Events and Presentations. The replay of the webcast will be accessible for 90 days. About ANI ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company committed to its mission of 'Serving Patients, Improving Lives" by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The Company is focused on delivering sustainable growth through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; its Generics business, which leverages R&D expertise, operational excellence, and U.S.-based manufacturing; and its Brands business. For more information, visit Investor Relations: Lisa M. Wilson, In-Site Communications, Inc.T: 212-452-2793 E: lwilson@ Source: ANI Pharmaceuticals, Inc.
Yahoo
12-05-2025
- Business
- Yahoo
ANI Pharmaceuticals to Participate at the H.C. Wainwright 3rd Annual BioConnect Conference at NASDAQ
PRINCETON, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ as follows: Date: Tuesday, May 20, 2025 Time: 1:30pm ET Webcast: Click Here To schedule a 1x1 meeting with management, please contact meetings@ The live and archived webcast will be accessible from the Company's website at under the Investors section under Events and Presentations. The replay of the webcast will be accessible for 90 days. About ANI ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company committed to its mission of 'Serving Patients, Improving Lives" by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The Company is focused on delivering sustainable growth through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; its Generics business, which leverages R&D expertise, operational excellence, and U.S.-based manufacturing; and its Brands business. For more information, visit Investor Relations: Lisa M. Wilson, In-Site Communications, Inc.T: 212-452-2793 E: lwilson@ Source: ANI Pharmaceuticals, in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
28-01-2025
- Business
- Yahoo
ANI Pharmaceuticals to Present at the Guggenheim Biotech Conference
PRINCETON, N.J., Jan. 28, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. ('ANI' or the 'Company') (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will host a fireside chat at the Guggenheim Biotech Conference in New York City as follows: Date: Wednesday, February 5, 2025 Time: 2:00pm EST Webcast: Click here The live and archived webcast will be accessible from the Company's website at under the Investors section under Events and Presentations. The replay of the webcast will be accessible for 60 days. About ANI Pharmaceuticals, Inc. ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company committed to its mission of 'Serving Patients, Improving Lives" by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The Company is focused on delivering sustainable growth through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; its Generics business, which leverages R&D expertise, operational excellence, and U.S.-based manufacturing; and its Established Brands business. For more information, visit Investor Relations: Lisa M. Wilson, In-Site Communications, Inc.T: 212-452-2793 E: lwilson@ Source: ANI Pharmaceuticals, in to access your portfolio
